Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Can Cochlear (COH) Shares Reach $220 Again?

The 52-week high price for Cochlear Limited (ASX: COH) shares is $221.44. Up almost 20% in the last three months, could Cochlear reach these highs again?

Over the past year, Cochlear Limited’s (ASX: COH) share price high is $221.44. With shares up almost 20% in the last three months, could Cochlear reach these highs again?

About Cochlear

Cochlear is one of the world’s leading medical businesses. Cochlear designs, manufactures and supplies the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant. Graeme Clark invented the first device in 1982, allowing first-user Graham Carrick to hear for the first time in 17 years. Some of the most recent modifications allow users to play sound from their phone directly into their implant.

The Positives

There is a lot to like about Cochlear. Through their technology and innovation, Cochlear has created a competitive advantage –- otherwise known as a moat –- and become the leading player in its industry. This comes with a lot of benefits, including brand awareness and some control over the prices they charge.

Cochlear also has a return on equity (ROE) of around 40%, far higher than most other comparable businesses. This shows that Cochlear has the ability to invest in projects that generate significant returns and value for shareholders.

Cochlear’s dividend yield is low, about 1.5%, but dividends have increased each year fairly consistently for some time now.

So, can Cochlear shares reach $220 again?

Valuation Looks Stretched

At the current price of $206.80, the valuation of Cochlear shares does look somewhat stretched. While the shares are only about 6.5% below the 52-week high, it might take some good news to get there.

Cochlear’s price-earnings (PE) ratio is 45x, significantly higher than other health care companies like CSL Limited (ASX: CSL), Ramsay Health Care Limited (ASX: RHC) and ResMed Inc (ASX: RMD). PE ratios are explained in this tutorial and video:

Based on a rough dividend valuation, the Cochlear share price also appears inflated. So, does this mean the shares are overvalued?

Ratios Aren’t Everything

Ratios and dividend valuations are only useful for getting a rough idea of a company’s value. The interesting comparison though is that Cochlear appears expensive next to a company like CSL, which is also a very high-quality company.

Cochlear shares may reach $220 again, but I wouldn’t feel confident buying at this price level. It’s a great business but I don’t believe there is a margin of safety right now.

I’d rather invest in one of the high-quality companies mentioned in the free report below.

[ls_content_block id=”14945″ para=”paragraphs”]

Disclosure: At the time of writing, Max does not own shares in any of the companies mentioned.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content